RxDoctor Payments DataLook up a doctor →

Maria Pimentel, APRN

Psychiatric/Mental Health · Hollywood, FLNPI 1710522735

Payments from drug & device makers

$17,906in general payments, 2019–2025

Across 849 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Alkermes, Inc.$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Johnson & Johnson$1K
  • plus $8K from 31 others

What the payments were for

  • Food & beverage$17,906100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,906 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$26,915
Medicare patients
46
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvanseLisdexamfetamine Dimesylate11$4,402
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine117$3,624
Lurasidone Hcl21$3,485
Doxepin Hcl84$2,830
Alprazolam396$2,429
Trazodone Hcl187$1,923
Clonazepam264$1,797
Buspirone Hcl153$1,639
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine35$1,588
Aripiprazole102$1,582
Duloxetine Hcl171$1,562
Escitalopram Oxalate186$1,390
Temazepam142$1,231
Sertraline Hcl231$1,220
Bupropion XlBupropion Hcl97$1,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$911$4,40211 claims
Almatica Pharma LLCSertraline Hcl$676$1,220231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →